Skip to main content
OpenTrials
Completed

NCT Number: NCT05504889

Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum

This study addresses the second aim of the grant (R01 HD0899455), which is to determine temporal changes in CYP3A4-mediated drug metabolism sequentially across pregnancy and after birth.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Northwestern University Asher Center for the Study and Treatment of Depressive Disorders

Chicago, Illinois, 60611, United States

About this study

This study addresses the second aim of the grant (R01 HD0899455), which is to determine temporal changes in CYP3A4-mediated drug metabolism sequentially across pregnancy and after birth.

In studies with human hepatocytes, we found that serum from women in the first trimester led to the highest CYP3A4 expression compared to those from the second or third trimester or after birth. Among the hormones with elevated plasma concentrations in early pregnancy, our studies revealed that thyroid hormone enhances CYP3A4 expression in human hepatocytes. Based on the results, we hypothesized that CYP3A4-mediated drug metabolism is highest during early pregnancy (compared to the later time points of pregnancy or postpartum period) in part due to changes in thyroid hormone concentration.

To test this hypothesis, we will evaluate the conversion of endogenous cholesterol to its 4β-hydroxycholesterol metabolite, which is facilitated by CYP3A4. To assess additional factors that affect CYP3A activity, we will obtain DNA. About 75% of African Americans, but only 10-20% of people of European descent, carry the active allele CYP3A5*1, which significantly increases the clearance of many CYP3A4/5 substrates, including the conversion of cholesterol to 4β-hydroxycholesterol.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English speaking
  • Pregnant before 14w0d OR postpartum between before 18w0d
  • Singleton gestation (as this will result in more consistent inter-individual measures)

Exclusion criteria

  • Chronic use of compounds that are substrates or inhibitors of CYP3A4 inhibitors, which will interfere with the concentrations and ratio. Potent inhibitors include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit. Inducers of CYP3A4 include phenobarbital, phenytoin, rifampicin, St. John's Wort and glucocorticoids.
  • Diagnosis of alcoholism or substance use.
  • Covid infection or within 4 weeks of positive test due to possible effect on hepatic function

Treatment and study plan

Primary outcomes

  1. Change in the endogenous metabolic ratio of 4β-hydroxycholesterol to cholesterol (4β-OHC/C, a marker of CYP3A activity) from early pregnancy through 17 weeks 6 days after delivery

    Time frame: Between 4-13 weeks of pregnancy, and 1-18 weeks postpartum

    plasma concentrations

Secondary outcomes

  1. Impact of active CYP3A5 phenotype on the 4β-hydroxycholesterol to cholesterol metabolic ratio

    Time frame: Between 4-13 weeks of pregnancy, and 1-18 weeks postpartum

    plasma concentrations

  2. Impact of estradiol concentrations on ratio in the early first trimester of pregnancy

    Time frame: Between 4-13 weeks of pregnancy, and 1-18 weeks postpartum

    plasma concentrations

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • Purdue University

Registry information

Acronym: CAMCAP

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 17, 2022
Registry last updated
Apr 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.